The U.S. House of Representatives has passed a bill aimed at restricting business with several Chinese biotech companies, including WuXi AppTec and BGI, citing national security concerns. Other companies named are China's MGI and its California-based subsidiary Complete Genomics. The Biosecure Act, which passed with a significant majority of 306...
Biotech Sector Shifts: India’s Role Explored
The U.S. biotech sector has seen significant growth in 2024, while China's biotech index has declined. This shift is partly attributed to the proposed BIOSECURE Act, introduced in January 2024, which aims to distance the U.S. from Chinese companies in the biotech industry, according to an aticle in Bioscpace The...
Biospace: U.S.’s BIOSECURE Act Will Open Opportunities for India’s CDMOs
A new article by Tyler Patchen writing for Biospace highlight how the BIOSECURE Act, a U.S. House bill that aims to restrict American biopharma companies from working with certain Chinese contract development and manufacturing organizations (CDMOs), particularly WuXi AppTec and WuXi Biologics will impact biopharma companies in the U.S. The...
India Grows in Importance as a Hub for Biopharmaceutical Manufacturing
India is growing in importance as a hub for biopharmaceutical manufacturing, particularly in the context of the proposed Biosecure Act in the United States. The Act aims to restrict U.S. biotech companies from working with Chinese firms, potentially driving more business towards Indian contract development and manufacturing organizations (CDMOs). A...